- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion: ORIGINAL: A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity (clinicaltrials.gov) - Nov 8, 2023
P3, N=1490, Completed,
Active, not recruiting --> Completed
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion, Trial completion date, Trial primary completion date: DIVAr (clinicaltrials.gov) - Nov 7, 2023
P=N/A, N=294, Completed,
Recruiting --> Completed | Trial completion date: Dec 2023 --> Sep 2023 | Trial primary completion date: Dec 2023 --> Sep 2023 Recruiting --> Completed | Trial completion date: Dec 2023 --> Sep 2023 | Trial primary completion date: Dec 2023 --> Sep 2023
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Site-specific PEGylation of recombinant tissue-type plasminogen activator. (Pubmed Central) - Nov 6, 2023
In this regard, we developed three polyethylene glycol (PEG)ylated tPA bioconjugates based on the recombinant human tPA drug Alteplase using site-specific conjugation strategies...Moreover, both bioconjugates with PEG-cysteine-modification showed 2-fold slower inhibition kinetics by PAI-1. All bioconjugates increased in hydrodynamic size as a critical requirement for half-life extension.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: New Wine in an Old Bottle: tPA for Ischemic Stroke Management. (Pubmed Central) - Nov 5, 2023
tPA forms the active principle of alteplase, a recombinant tissue-type plasminogen activator (rtPA), which is well known for its intravascular thrombolytic activity...In this comment, we focus on possible hypotheses about why and how tPA promotes ischemic neuronal survival in a comprehensive view. The text provides a holistic picture of the functions of tPA and enlists the considerations for the future, which might attract more attention toward the therapeutic potential of tPA in AIS.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Acute management of childhood stroke. (Pubmed Central) - Nov 3, 2023
Among Chinese stroke patients treated with intravenous alteplase, SBP after alteplase was associated with clinical outcomes, which were affected by age and sex. There have been significant advances in the hyperacute care of children with ischemic stroke and early diagnosis and targeted management are of the upmost importance in improving long-term outcomes.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective data, Journal: Tenecteplase, 0.4?mg/kg, in Moderate and Severe Acute Ischemic Stroke: A Pooled Analysis of NOR-TEST and NOR-TEST 2A. (Pubmed Central) - Nov 3, 2023
P3
A lower tenecteplase dose should be tested in future trials. Registration URL: https://www.clinicaltrials.gov; Unique identifiers: NCT01949948, NCT03854500.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed, Trial completion date, Trial primary completion date: THEIA: A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion (clinicaltrials.gov) - Nov 3, 2023
P3, N=70, Active, not recruiting,
Registration URL: https://www.clinicaltrials.gov; Unique identifiers: NCT01949948, NCT03854500. Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Jan 2024 | Trial primary completion date: Oct 2024 --> Jan 2024
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion, Enrollment change: PLATyPuS: Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis (clinicaltrials.gov) - Nov 1, 2023
P2, N=40, Completed,
Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Jan 2024 | Trial primary completion date: Oct 2024 --> Jan 2024 Active, not recruiting --> Completed | N=13 --> 40
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: HummingFlow: novel single twist-drill access for ventricular drainage, irrigation, monitoring, and automated local drug delivery in subarachnoid hemorrhage. (Pubmed Central) - Oct 23, 2023
Combined CSF drainage, irrigation, multimodality monitoring, and automated local drug delivery are feasible using a single twist-drill hole device. Further investigation of irrigation settings and treatment approaches in high-risk cases is warranted.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Intracranial atherosclerotic disease: current management strategies. (Pubmed Central) - Oct 9, 2023
Another critical question that arises is the treatment of acute ischaemic stroke due to large vessel occlusion with underlying intracranial atherosclerosis, is the treatment and clinical diagnosis the same as for other aetiologies of stroke (i.e. extracranial disease and nonvalvular atrial fibrillation)? Consequently, secondary prevention of patients with ischaemic stroke or transient ischaemic attack will be divided into medical therapy, risk factor control, and endovascular and surgical treatment options.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: The Application of Data Envelopment Analysis to Emergency Departments and Management of Emergency Conditions: A Narrative Review. (Pubmed Central) - Sep 28, 2023
We thoroughly assess the methodological basis of the papers, offering detailed explanations regarding the applied models, selected inputs and outputs, and all relevant methodologies. In conclusion, we explore several ways to enhance DEA's status, transforming it from a mere technical application into a strong methodology that can be utilized by healthcare managers and decision-makers.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective data, Review, Journal: Efficacy and safety of tenecteplase in comparison to alteplase in acute ischemic stroke: A systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) - Sep 15, 2023
SEP appears to be a feasible and safe thromboprophylaxis method to improve thrombosis-free patency for AV access with recurrent thrombosis. Based on our meta-analysis, tenecteplase has similar efficacy and safety to alteplase, with a more promising effect in patients with LVO.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial termination: NOR-TEST 2: The Norwegian Tenecteplase Stroke Trial 2 (clinicaltrials.gov) - Sep 15, 2023
P3, N=201, Terminated,
Based on our meta-analysis, tenecteplase has similar efficacy and safety to alteplase, with a more promising effect in patients with LVO. Recruiting --> Terminated; Per protocol safety analysis 200 patients showed a significant difference in bleeding rates between the two drug groups.
- |||||||||| Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Effects of simultaneous use of Cerebrolysin and alteplase on hemorrhagic transformation of brain infarction and functional outcome in stroke patients: CEREHETIS, a randomized, multicenter pilot trial (Pubmed Central) - Sep 12, 2023
The combination of Cerebrolysin and Alteplase was safe and significantly reduced the rate of symptomatic HT and improved early neurological deficit. However, no difference in functional outcome was found on day 90, but there was a trend towards favorable functional outcome.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness of tenecteplase versus alteplase for acute ischemic stroke. (Pubmed Central) - Sep 2, 2023
Tenecteplase treatment was cost-effective for all AIS patients (including AIS patients with LVO) compared to alteplase. The finding supports the broader use of tenecteplase in acute stroke care, as health outcomes improve at acceptable costs while having practical advantages, and a similar safety profile.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion: CRAD-001-03: A Study of r-PA Treating Patients With Acute Ischemic Stroke?RAISE? (clinicaltrials.gov) - Aug 31, 2023
P3, N=1412, Completed,
Up-to-date treatment of stroke which includes timely reperfusion and neurometabolic support of recovery leads to the rapid manifest regression of the neurological deficit and to the improvement in functioning and activity of patients with cerebral infarction. Active, not recruiting --> Completed
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Early Recanalization Among Patients Undergoing Bridging Therapy With Tenecteplase or Alteplase. (Pubmed Central) - Aug 25, 2023
Both thrombolytics achieved ER in one-fifth of patients with large-vessel occlusion acute ischemic stroke without significant interaction with IVT-to-ER time and occlusion site. Compared with alteplase, tenecteplase was associated with a 2-fold higher likelihood of ER in larger thrombi.
- |||||||||| nerinetide (NA 1) / NoNO, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal, HEOR: Health economic impact of Nerinetide in addition to mechanical thrombectomy without concurrent alteplase. (Pubmed Central) - Aug 17, 2023
Compared with alteplase, tenecteplase was associated with a 2-fold higher likelihood of ER in larger thrombi. Treating patients with a cerebroprotectant, such as Nerinetide, in addition to endovascular treatmentl in patients who cannot receive intravenous alteplase may be beneficial from a health-economic standpoint.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Neurologic and Psychiatric Manifestations of Bradykinin-Mediated Angioedema: Old and New Challenges. (Pubmed Central) - Aug 16, 2023
Finally, most patients with HAE have higher levels of psychological distress, anxiety, and depression. With this review, we aimed to provide an organized and detailed analysis of the existing literature on neurologic and psychiatric manifestations of HAE to shed light on these potentially invalidating symptoms and lay the foundation for further personalized diagnostic pathways for patients affected by this protean disease.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase. (Pubmed Central) - Aug 14, 2023
Tenecteplase, a revised version of alteplase, is a potential alternative IV thrombolytic agent that has benefits over alteplase. The aim of this mini-review is to summarize the advancements in IV thrombolysis for severe ischemic stroke, specifically the development and transition from alteplase to tenecteplase.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open: PEARL: Intra-arterial Alteplase for Acute Ischemic Stroke After Mechanical Thrombectomy (clinicaltrials.gov) - Aug 14, 2023
P3, N=324, Recruiting,
The aim of this mini-review is to summarize the advancements in IV thrombolysis for severe ischemic stroke, specifically the development and transition from alteplase to tenecteplase. Not yet recruiting --> Recruiting
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal, Adverse events, Real-world evidence, Real-world: Comparing adverse Events of tenecteplase and alteplase: A Real-World analysis of the FDA adverse Event Reporting System (FAERS). (Pubmed Central) - Aug 9, 2023
Additionally, previously unreported ocular ADRs and pneumonia were identified, providing valuable insights into the relationship between ADRs and the use of these thrombolytic drugs. These findings underscore the importance of continuous monitoring and effective detection of AEs to ultimately enhance the safety of AIS patients undergoing thrombolytic therapy.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective data, Review, Journal: Tenecteplase vs. Alteplase for Intravenous Thrombolytic Therapy of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. (Pubmed Central) - Aug 8, 2023
This meta-analysis showed that tenecteplase was not inferior to alteplase in early thrombolytic therapy in patients with AIS, and was even better than alteplase on some efficacy outcomes with no significant differences in safety. However, as a result of some inherent limitations of this study, more high-quality prospective clinical studies are needed to confirm these results.
|
